COMPANY HISTORY

  • 2015.06
  • 2015.12
  • 2016.10
  • 2017.03
  • 2017.12
  • 2018.05
  • 2018.06
  • 2018.07
  • 2018.09
  • 2018.09
  • 2018.10
  • 2018.11
  • 2018.11
  • 2018.12
  • 2019.01
  • 2019.02
  • 2019.03
  • 2019.04
  • 2019.06
  • 2019.06
  • 2019.08
  • 2019.09
  • 2019.10
  • 2019.12
  • 2019.12
  • 2019.12
  • 2020.03
  • 2020.07
  • 2020.07
  • 2020.08
  • 2020.09
  • 2020.10
  • 2020.11
  • 2020.11
  • 2020.11
  • 2020.11
  • 2020.12
  • 2021.01
  • 2021.02
  • 2021.04
  • Hangzhou Sumgen Biotech Co., Ltd. was Founded
  • Sumgen Biotech Applied for the First Invention Patent
  • Beijing R&D Center, Sumgen Monoclonal Antibody (Beijing) Biotech Co., Ltd. was Built
  • Sumgen Biotech Completed Angel Investment
  • Sumgen Biotech was Selected to be Part of the Hangzhou Riverside “5050” Plan
  • Dr. Lv, Founder of Sumgen Biotech, was Honored Among the Third Batch of Leading Talents of the “Innovative and Entrepreneur Talents Project • E-town Talents”
  • Sumgen Biotech Vompleted Series A Funding in Jun. 2018, with Shanghai CCB Equity Investment Management Co., Ltd. as the Sole Investor.
  • IND (Investigational New Drug) Application of the First R&D Project of Sumgen Biotech was Filed to CDE (Center for Drug Evaluation in China)
  • Sumgen Biotech was Granted the First National Invention Patent
  • The First Independent R&D Project of Sumgen Biotech was Granted Clinical Trial Permission by CDE
  • The Official Website and WeChat Account of Sumgen Biotech were Launched
  • Sumgen Biotech Reached a Project Joint Development Agreement with CSPC
  • The Hangzhou CMC R&D Center was Officially Established
  • Sumgen Biotech was Designated as One of the Science and Technology SMEs in Zhejiang Province
  • Sumgen Biotech Completed Series A+ Funding in Jan. 2019, with China National Biotech Group (CNBG) as the Strategic Investor.
  • Dr. Lv Ming, Founder of Sumgen Biotech, was Honored Among the Fourth Batch of Outstanding Young Talents Under the “National Ten Thousand Talents Plan” in Feb. 2019. Dr. Lv Ming is 0ne of the 7 Enterprise Representatives Elected Nationwide, and the Only Biomedicine Enterprise Representative of Zhejiang Province.
  • First Subject was Enrolled in the PD1 Antibody Project (SG001) Jointly Developed by Sumgen Biotech and CSPC
  • The Guangzhou R&D Center was Officially Established
  • Sumgen Biotech was Designated by the National Intellectual Property Management System
  • Sumgen Biotech was Selected to Participate in the Theme Exhibition of 2019 National Mass Innovation and Entrepreneurship Week
  • Sumgen Biotech was Designated as Hangzhou Enterprise High-tech R&D Center
  • Sumgen Biotech was Recognized as One of China's Top 50 Medical and Healthcare Innovation Enterprises of 2009
  • Sumgen Biotech was Designated as Hangzhou High-Tech Enterprise
  • SG404 Project of Sumgen Biotech was Listed Among the 2020 Key R&D Projects of Zhejiang and Obtained a Support Grant
  • Hangzhou Sumgen Biotech Co., Ltd. and Sumgen Monoclonal Antibody (Beijing) Biotech Co., Ltd. were Both Recognized as National High-tech Enterprises.
  • Sumgen Biotech was designated as Hangzhou Patent Demonstration Enterprise
  • Hangzhou Sumgen Biotech Co., Ltd. and CNBG Set Up the Joint Venture CNBG Sumgen Biopharmaceutical (Hangzhou) Co., Ltd. (“CNBG Sumgen”)
  • The Application for Phase 1 Clinical Trial of SG301(an anti-CD38 monoclonal antibody) in China was Accepted
  • Sumgen Biotech was designated as a Technologically Advanced Small and Medium-sized Enterprise of Beijing
  • The Construction of an Antibody Industrialization Base was launched with Government Support
  • The Series B Funding (RMB 220 million) was Completed in Sep. 2020, Which Accelerated the Development and Industrialization of Innovative Products
  • The SG12473 Project was Submitted for PreIND
  • The Innovative Drug SG301 of Sumgen Biotech was Approved by the US FDA for a Phase I Clinical Trial
  • The First Innovative Drug SG404 Injection of CNBG Sumgen was Approved for Clinical Trials in China
  • The Company was Recognized as One of the Top 50 Innovative Biomedicine Enterprises of 2020 in China
  • The Company was Selected as a Membership Unit of the Biomedical Innovation Alliance (BIA) of Hangzhou High-tech Zone (Binjiang)
  • The Clinical Trial of the Innovative Drug SG404 was Initiated at Beijing Cancer Hospital
  • The First Subject was Enrolled in the Clinical Trial of SG404
  • The Innovative Drug SG404 was Approved by the US FDA for a Phase I Clinical Trial
  • Clinical Trials of the First Bispecific Antibody SG12473 by Sumgen Biotech Was Approved in China and the United States

Copyright Rm. 301, F3, Building C, Block 2, No. 688, Bin'an Road, Changhe Zhejiang ICP Filing No. 18039044